Tag: non-small cell lung cancer

Latest FDA Pembrolizumab Approval Expands Label to Cutaneous SCCs

The Food and Drug Administration has approved pembrolizumab (Keytruda) monotherapy for locally advanced cutaneous squamous cell carcinoma (cSCC) that can’t be cured by surgery or...

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU

Combination therapy with the immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy) is now approved in the European Union for the first-line treatment of adults with unresectable...

First Drug for Lung Cancer With KRAS Mutation Gains FDA Approval

The first drug to target KRAS mutations in non-small cell lung cancer (NSCLC) has been approved by the US Food and Drug Administration. KRAS mutations...

FDA OKs First Targeted Therapy for Subset of Patients With NSCLC

The US Food and Drug Administration (FDA) today granted an accelerated approval for amivantamab (Rybrevant) as the first targeted treatment for patients with non–small cell...

FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression

The US Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for the treatment of advanced non–small cell lung cancer (NSCLC). Specifically, the indication is...

Amivantamab Shows Promise in Challenging EGFR-Mutated NSCLC

A novel drug, the immune cell-directing antibody amivantamab (under development by Janssen), has shown promise for the treatment of patients with non–small cell lung cancer...

Real-World Results With Checkpoint Inhibitors Inferior to CT Data

Real-world survival outcomes for cancer patients on immune checkpoint inhibitors (ICIs) are inferior to outcomes reported in patients on clinical trials of ICIs, according to research...

Selpercatinib ‘Poised to Alter the Landscape’ of RET+ve Cancers

Clinical data for the first-ever RET inhibitor, selpercatinib (Retevmo), show efficacy in two groups of patients with cancer ― those with RET fusion–positive non–small cell...

Performance Status, Molecular Testing Key to Cancer Prognosis

Performance status and molecular testing results are key tools in prognosticating for patients with newly diagnosed metastatic solid tumors, according to Sam Brondfield, MD, MA,...

No Increase in Risk of Death From COVID-19 in Cancer Patients

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Immune checkpoint inhibition was not associated with an increased mortality risk...

‘Staging the Aging,’ Immuno-Combo for Lung Cancer

Here are the most important stories that Medscape Oncology’s editors picked for you to read today: “Staging the Aging” Cancer Benefits Proven. Payment Coming? Three...

Olaparib in Ovarian Cancer, Smoking and Lung Cancer

Here are the most important stories that Medscape Oncology’s editors picked for you to read today: A New Era for Ovarian Cancer Olaparib maintenance therapy...

FDA Approves Chemo-Free Combo for Lung Cancer

The US Food and Drug Administration (FDA) today approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) as first-line treatment for...

Capmatinib Shows Impressive Results in METex14-Mutated NSCLC

Capmatinib produced rapid, deep responses in patients with advanced non–small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations, according to a presentation...

Osimertinib May Be Beneficial for NSCLC Patients With Intracranial Metastasis

NEW YORK (Reuters Health) – Results of a systematic review and meta-analysis support a possible role for osimertinib in the management of non-small-cell lung cancer...